Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Aptar Pharma advances digital offerings

Partners up with digital therapeutics company Propeller Health

AptarFurther strengthening pharma’s stance in the digital health field, prescription drug and consumer healthcare group Aptar Pharma has teamed up with Propeller Health in a bid to develop digital medicines in multiple therapeutic areas.

The “comprehensive” platform, which will span inhaled, injectable, nasal and dermal medicine delivery forms, will combine software with connected drug delivery devices.

Aptar Pharma will work with its new partner together with pharmaceutical and healthcare associates to accelerate the development, manufacturing and commercialisation of digital medicines for marketed and pipeline brands.

Propeller and Aptar Pharma will co-market the platform, with the former managing digital services and the latter handling device development, manufacturing and supply chain.

David Van Sickle, co-founder and CEO of Propeller, said: “Propeller draws on nearly a decade of experience pioneering digital respiratory medicines and putting them to work in healthcare organizations around the world.

“Our end-to-end infrastructure enables fast, flexible and secure development and commercialisation of digital medicines.”

Digital therapeutics, dubbed ‘digiceuticals’, has been somewhat of a focus for the industry as of late, with studies showing that this particular therapeutic advancement can help personalise treatments, monitor patients in real-time, detect day-to-day changes in disease conditions and increase patient adherence.

Salim Haffar, president of Aptar Pharma, commented: we are excited to broaden our offerings as we continue this journey towards improved patient care and clinical outcomes by growing our partnership with Propeller Health the leader in their field of digital therapeutics

The two companies initially partnered in 2016 to develop, what the companies say, is the world’s first fully-integrated connected metered dose inhaler (cMDI).

In addition to the expanded partnership, Aptar Pharma has made a strategic equity investment of $10m in Propeller Health during their latest funding round.

Article by
Gemma Jones

7th June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics